

A Study of the Epoxidation of Cycloolefins by the *t*-BuOH Copper-Permanganate System

Younis Baqi, Simon Giroux, and E. J. Corey*

Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street Cambridge, Massachusetts 02138

Table of content:


1. Materials and Methods	page S1
2. Experimental procedures	page S2
3. References	page S6
4. Copies of selected ¹H and ¹³C NMR spectras	page S7

1. Materials and Methods. Unless stated otherwise, reactions were performed in flame dried glassware under a slight positive pressure of nitrogen using freshly distilled, dry solvent. Commercial grade reagents and solvents were used without further purification except as indicated below. Methanol (MeOH) was distilled over CaSO₄. Dichloromethane (CH₂Cl₂), benzene, and triethylamine (Et₃N) were distilled over calcium hydride (CaH₂). Ether (Et₂O) and tetrahydrofuran (THF) were purified by Seco Solvent Systems. Thin layer chromatography (TLC) was performed using E. Merck silica gel 60 F₂₅₄ precoated plates (0.25 mm). Flash chromatography was performed using Baker silica gel (40 μm particle size). ¹H NMR spectra were recorded on Varian Mercury 400 (400 MHz) or Unity/INOVA 500 (500 MHz) spectrometers and chemical shifts are reported in ppm downfield from tetramethylsilane with the solvent resonance as internal standard (δ 7.26 ppm for CDCl₃). ¹³C NMR spectra were recorded on Varian Mercury 400 (100 MHz) or Unity/INOVA 500 (125 MHz) spectrometers with proton decoupling. Chemical shifts are reported in ppm downfield from tetramethylsilane with the solvent as internal (δ 77.16 ppm for CDCl₃). IR spectra were recorded on Avatar 360 FT-IR spectrometer. Low-resolution and high-resolution mass spectral analyses were performed at the Harvard University Mass Spectrometry Center. Optical rotations were measured with a Perkin-Elmer 241 polarimeter at the indicated temperature with a sodium lamp (D line, 589 nm). Melting points (m.p.) are uncorrected and were recorded on a Thomas-Hoover Unimelt capillary melting point apparatus.

2. Experimental procedures

2.1 Studies on Δ^5 model.

Epoxidation of cholesteryl benzoate:



Epoxidation with $m\text{-CPBA}$:

To a stirred solution of cholesteryl benzoate (100 mg, 0.20 mmol) in CH_2Cl_2 (2 mL) was added $m\text{-CPBA}$ (52.7 mg, 0.31 mmol) at $0\text{ }^\circ\text{C}$ the reaction was completed after 2 h stirring at $0\text{ }^\circ\text{C}$. The reaction was quenched by addition of saturated solution of K_2CO_3 (aq.) (2 mL) and the aqueous phase was extracted with CH_2Cl_2 (3 x 10 mL). The organic phase was dried over Na_2SO_4 and concentrated to dryness to afford a 6:4 mixture of cholestan-5 α ,6 α -epoxy-3 β -ol benzoate and cholestan-5 β ,6 β -epoxy-3 β -ol benzoate (98 mg, 95%) as a white solid. ^1H NMR (500 MHz, CDCl_3) δ 8.02 (d, 2H, $J = 7.5\text{ Hz}$), 7.53 (dd, 1H, $J = 7.1\text{ Hz}$, $J = 6.9\text{ Hz}$), 7.42 (m, 2H), 5.21 (1H, m, 3CH, α -epoxide), 5.05 (1H, m, 3CH, β -epoxide), 3.12 (1H, br, 6CH, β -epoxide)*, 2.93 (1H, d, $J = 4.4\text{ Hz}$, 6CH, α -epoxide)*, 2.25 (m, 1H), 2.08 (m, 1H), 1.95-1.11 (m, 16H), 1.05 (s, 3H, CH_3), 0.98 (m, 2H), 0.87 (m, 6H, 2- CH_3), 0.62 (s, 3H, CH_3); ^{13}C NMR (125 MHz, CDCl_3) δ 166.2, 165.9, 133.1, 133.0, 131.0, 130.7, 129.79, 129.76, 128.54, 128.48, 72.2, 72.1, 65.4, 63.8, 62.8, 59.4, 57.0, 56.4, 56.1, 51.2, 42.7, 42.6, 42.5, 40.0, 39.7, 38.3, 36.9, 36.5, 36.4, 36.01, 35.97, 35.33, 35.29, 32.7, 32.4, 30.13, 29.99, 29.0, 28.4, 28.3, 28.3, 27.6, 24.4, 24.3, 24.1, 24.0, 23.1, 22.8, 22.2, 20.9, 18.92, 18.88, 17.3, 16.2, 12.1, 12.0; IR (cm^{-1}): 2932, 2867, 1712, 1466, 1450, 1275, 1117, 1026, 709.

Epoxidation with $\text{KMnO}_4\text{-CuSO}_4$:

A mixture of KMnO_4 (600 mg) and $\text{CuSO}_4\cdot 5\text{H}_2\text{O}$ (300 mg) was ground to a fine powder and transferred to a reaction flask. Water (0.03 mL) was added, and mixed very well. To a stirred suspension of this mixture in CH_2Cl_2 (2 mL) was added cholesteryl benzoate (100 mg, 0.20 mmol) and $t\text{-BuOH}$ (0.15 mL). The mixture was then refluxed for 1.25 h. After cooling the

mixture was filtered through a pad of Celite[®] and washed with CH₂Cl₂ (3x10 mL) to give, after concentration, cholestan-5 β ,6 β -epoxy-3 β -ol benzoate **2** (77 mg, 75%) as a white solid. $[\alpha]_D = +10$ (CHCl₃, $c = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, 2H, $J = 7.3$ Hz), 7.53 (m, 1H), 7.42 (m, 2H), 5.05 (1H, m, 3CH), 3.11 (1H, br, 6CH, β -epoxide, $\omega^{1/2} = 2.1$ Hz)^{*}, 2.27 (dd, 1H, $J = 12.7$ Hz, $J = 12.2$ Hz), 2.09 (d, 1H, $J = 14.6$ Hz), 1.98 (m, 2H), 1.82 (m, 1H), 1.64-1.04 (m, 14H), 1.03 (s, 3H, CH₃), 0.84 (m, 6H, 2CH₃), 0.64 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃) δ 166.2, 133.1, 130.7, 129.8, 128.54, 128.48, 72.1, 63.8, 62.8, 56.4, 51.2, 42.5, 40.0, 39.7, 38.3, 36.9, 36.4, 36.0, 35.3, 32.7, 30.0, 28.4, 28.2, 27.6, 24.4, 24.1, 23.1, 22.8, 22.2, 18.9, 17.3, 12.0; m.p. 168-170 °C, (lit. m.p. 172-174 °C)¹; MS (ES +) m/z (%): 507.4 (M + H⁺, 100).

^{*} The equatorial hydrogen (6CH) in the β -epoxide isomer is easily distinguishable than the axial hydrogen (6CH) in the α -epoxide; 6CH in β -epoxide is downfield (3.11 ppm) and broad ($\omega^{1/2} = 2.1$ Hz), whilst 6CH in α -epoxide is upfield (2.93 ppm) and a clear doublet ($J = 4.3$ Hz).²

Preparation of Cu(MnO₄)₂


To a stirred solution of KMnO₄ (13.3 g, 84.3 mmol) in H₂O (200 mL) was added Cu(BF₄)₂ (10.0 g, 42.1 mmol) in H₂O (10 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 10 minutes and then filtered to remove the precipitate of KBF₄. Evaporation of H₂O gave Cu(MnO₄)₂ (10g, 79%) as a grey-brown powder. Cu(MnO₄)₂ was also synthesized using a literature method,⁶ but we found this to be much less convenient.

Epoxidation with Cu(MnO₄)₂:

Cholesteryl benzoate (50 mg, 0.102 mmol) was dissolved in CH₂Cl₂ (0.5 mL) and *t*-BuOH (1.5 mL). To this stirred solution, Cu(MnO₄)₂ (46 mg, 0.153 mmol) was added at room temperature. Stirring was continued at room temperature for 1 h. The resulting solution was passed through a short pad of silica gel which was eluted with CH₂Cl₂ and ether. Evaporation in vacuo gave cholestan-5 β ,6 β -epoxy-3 β -ol benzoate **2** and cholestan-5 α ,6 α -epoxy-3 β -ol benzoate in a 6:1 ratio as a white solid (55 mg, quant) with physical data identical as above.

2.2 Studies on Δ^7 model.

Epoxidation of Δ^7 acetate:



Epoxidation with $m\text{-CPBA}$:

To a stirred solution of Δ^7 acetate (100 mg, 0.23 mmol) in CH_2Cl_2 (2 mL) was added $m\text{-CPBA}$ (60 mg, 0.35 mmol) at $0\text{ }^\circ\text{C}$. After 2 h of stirring at $0\text{ }^\circ\text{C}$, the mixture was treated with saturated aq. solution of K_2CO_3 (2 mL) and the aqueous phase was extracted with CH_2Cl_2 (3x10 mL). The organic phase was dried over Na_2SO_4 and concentrated to dryness to afford cholestan-7 α ,8 α -epoxy-3 β -ol acetate **3** as a white solid (98 mg, 95%).


Epoxidation with $\text{KMnO}_4\text{-CuSO}_4$:

A mixture of KMnO_4 (420 mg) and $\text{CuSO}_4\cdot 5\text{H}_2\text{O}$ (210 mg) was ground to a fine powder and transferred to a reaction flask. H_2O (0.025 mL) was added, and mixed very well. To a stirred suspension of this mixture in CH_2Cl_2 (1.5 mL) at $23\text{ }^\circ\text{C}$ was added Δ^7 acetate (100 mg, 0.23 mmol) and $t\text{-BuOH}$ (0.10 mL). The mixture was refluxed for 1.25 h, cooled and treated with saturated $\text{Na}_2\text{S}_2\text{O}_4$ (aq), filtered through a pad of Celite[®] and washed with CH_2Cl_2 (3x10 mL). The organic phase was separated and the aqueous phase was extracted with CH_2Cl_2 (3x10 mL). The combined organic phase was dried over Na_2SO_4 and evaporated to give cholestan-7 α ,8 α -epoxy-3 β -ol acetate **3** (99 mg, 95%) as a white solid. ^1H NMR (500 MHz, CDCl_3) δ 4.61 (br, 1H, 3CH), 3.26 (1H, br, 7CH, α -epoxide)*, 1.98 (s, 3H, CH_3), 1.73-1.19 (m, 26H), 1.09 (s, 3H, CH_3), 0.84 (m, 9H, 3 CH_3), 0.68 (s, 3H, CH_3). ^{13}C NMR (125 MHz, CDCl_3) δ 170.7, 73.4, 62.5, 59.2, 56.2, 54.6, 46.2, 42.8, 39.7, 38.6, 37.5, 36.3, 36.2, 34.4, 33.9, 33.4, 30.0, 28.2, 27.6, 27.5, 24.1, 23.0, 22.8, 22.4, 21.6, 19.1, 15.1, 12.7; IR (cm^{-1}): 2948, 2867, 1731, 1467, 1364, 1240, 1029, 736; m.p. $207\text{-}210\text{ }^\circ\text{C}$ (lit. m.p. $95\text{-}97\text{ }^\circ\text{C}$).³; MS (ES +) m/z (%): 445.4 ($\text{M} + \text{H}^+$, 10), 427.3 ($\text{M} - \text{H}_2\text{O} + \text{H}^+$, 100).

* The axial hydrogen (7CH) in the α -epoxide isomer is easily distinguishable than the equatorial hydrogen (7CH) in the β -epoxide; 7CH in α -epoxide is down field (3.26 ppm) and broad ($\omega^{1/2} = 2.1$ Hz), whilst 7CH in β -epoxide is upfield (2.80 ppm) and doublet ($J = 5.3$ Hz).³


2.5 Studies on $\Delta^{3,5}$ model.

Epoxidation of 3,5-Cholestadiene ($\Delta^{3,5}$ model):



A mixture of KMnO_4 (1.4 g) and $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.7 g) was ground to a fine powder and transferred to a reaction flask. H_2O (0.04 mL) was added, and mixed very well. To a stirred suspension of this mixture in CH_2Cl_2 (10 mL) was added 3,5-cholestadiene⁸ (369 mg, 1 mmol) at r.t., followed by the addition of *tert*-butanol (0.4 mL). The solution was stirred at r.t. for 3h by which time TLC indicated that the epoxidation was completed. The reaction was quenched with isopropyl alcohol, filtered through a pad of Celite[®] and washed with EtOAc (7x10 mL). Evaporation gave a crude mixture of **4** (174 mg, 46%), which used in the next step. Analysis of the crude: ^1H NMR (500 MHz, CDCl_3) δ 6.02 (m, 1H), 4.95 (m, 1H), 3.12 (br, 1H, 6CH, β -epoxide), 2.20-1.78 (m, 6H), 1.60-0.98 (m, 18H), 0.97 (s, 3H, CH_3), 0.88 (m, 6H, 2 CH_3), 0.66 (s, 3H, CH_3). ^{13}C NMR (125 MHz, CDCl_3) δ 132.9, 130.8, 62.1, 56.51, 56.47, 50.2, 42.6, 40.0, 39.7, 36.5, 36.4, 36.01, 35.97, 34.1, 32.5, 29.9, 28.4, 28.2, 24.5, 24.0, 23.0, 22.8, 22.3, 21.6, 18.9, 16.5, 12.0; IR (cm^{-1}): 2933, 2867, 1707, 1466, 1351, 1025, 737, 703.

Hydrogenation and Acetylation of Cholest-5 β ,6 β -epoxy-3-ene:



To a stirred solution of cholest-5 β ,6 β -epoxy-3-ene **4** (170 mg, 0.44 mmol) in EtOAc (5 mL) was added Pd/C (28 mg, 10 wt. %). The reaction mixture was placed under an atmosphere of H_2 (1 atm) and the mixture was stirred for 24 h. After filtration through a pad of Celite[®],

washing with EtOAc (3x5 mL) and concentration, the residue was purified by flash chromatography (hexanes/EtOAc; 10:0 → 8:2) to afford coprostan-6 β -ol (76 mg, 45%) as a thick syrup. To a stirred solution of coprostan-6 β -ol (75 mg, 0.19 mmol) in CH₂Cl₂ (4 mL) was added DMAP (3 mg, 0.02 mmol) and Et₃N (0.01 mL, 0.57 mmol) at r.t. To this mixture acetic anhydride (0.05 mL, 0.29 mmol) was added. The reaction mixture was stirred for 1h and then treated with saturated NH₄Cl (5 mL). The aqueous phase was extracted with CH₂Cl₂ (3x5 mL) and the organic phase was dried with Na₂SO₄. Evaporation gave a crude mixture (88 mg), which purified by flash chromatography (100:0 to 90:10 hexanes/EtOAc) to afford coprostan-6 β -ol acetate **5** (80 mg, 96%) as a white solid. $[\alpha]_D = +16$ (CHCl₃, $c = 0.55$), lit. $[\alpha]_D = +22$ ($c = 0.55$).⁴; ¹H NMR (500 MHz, CDCl₃) δ 4.70 (d, 1H, 6CH, $J = 1.8$ Hz), 2.03 (s, 3H, CH₃), 1.99 (m, 1H), 1.82 (m, 1H), 1.70 (m, 3H), 1.56 (m, 4H), 1.42-1.03 (m, 10H), 0.99 (s, 3H, CH₃), 0.88 (m, 6H, 2CH₃), 0.68 (s, 3H, CH₃). ¹³C NMR (125 MHz, CDCl₃) δ 170.8, 76.0, 56.6, 65.5, 46.8, 43.0, 40.7, 40.4, 39.8, 37.8, 36.4, 36.0, 35.2, 32.0, 31.7, 28.5, 28.2, 26.8, 26.7, 26.1, 24.5, 24.1, 23.0, 22.8, 22.0, 21.0, 20.8, 18.9, 12.4; IR (cm⁻¹): 2929, 2849, 1739, 1462, 1369, 1244, 1016, 737; m.p. 104-106 °C (lit. m.p. 109-111 °C).⁴ MS (ES +) m/z (%): 372.4 ([M – OAc]⁺, 30), 371.4 (M – OAc – H)⁺, 100).

Epoxidation of Stigmasteryl Acetate with Cu(MnO₄)₂.

Stigmasteryl acetate (50 mg, 0.11 mmol) was dissolved in 0.5 mL of CH₂Cl₂, and treated with 1.5 mL of *t*-BuOH. To this stirred solution, Cu(MnO₄)₂ (50 mg, 0.165 mmol) was added at room temperature. Stirring was continued at room temperature for 1 h. The resulting solution was passed through a short pad of silica gel which was eluted with CH₂Cl₂ and ether. Evaporation of the solvent *in vacuo* gave 5 β ,6 β -epoxy-derivative **6** and 5 α ,6 α -epoxy-derivative in a 6:1 ratio as a white solid (51 mg, 99%) with physical data identical to the literature.⁵

3. References :

- (1) Marchon, J.-C.; Ramasseul, R. *Synthesis* **1989**, 389-391.
- (2) Yamada, T.; Imagawa, K.; Mukaiyama, T. *Chem. Lett.* **1992**, 2109-2112.
- (3) Eguchi, S.; Yamaguchi, S.; Furuya, M.; Morisaki, M. *Chem. Pharm. Bull.* **1988**, 36, 2813-2818.
- (4) Jones, D.N.; Shoppee, C.W.; Summers, G.H.R.; *J. Chem. Soc.* **1955**, 2876-2887.
- (5) Syamala, M. S.; Das, J.; Baskaran, S.; Chandrasekaran, S. *J. Org. Chem.* **1992**, 57, 1928-1930.
- (6) Kotai, L  ; Sajo, I. E.; Gacs, I.; Sharma, P. K.; Banerji, K. K. *Z. Anorg. Allg. Chem.* **2007**, 633, 1257.

4. Copies of selected ^1H and ^{13}C NMR spectras:

